author-photo

Glen D. Raffel

University of Massachusetts Medical School
UMass Memorial Health Care

49

Papers

309

Citations

Citation Trend

Filter By

Papers (49) Sort By

Journal Conference Others

MGTA-456, A CD34 Expanded Cord Blood Product, Permits Selection of Better HLA Matched Units and Results in Rapid Hematopoietic Recovery, Uniform Engraftment and Reduced Graft-Versus-Host Disease in Adults with High-Risk Hematologic Malignancies

2021
Show All
- Source
- Cite
- Save
Citations (0)
Mgta-456, a Cell Therapy Utilizing Expansion of CD34+ Hematopoietic Stem Cells (HSC), Improves HLA Matching for Adult Recipients, Promotes Faster Hematopoietic Recovery and Enables Uniform Engraftment with Less Acute Graft-Vs-Host Disease (GVHD)

2020 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (0)
Mgta-456 Cell Therapy in Inherited Metabolic Disease (IMD) Yields Rapid and Durable Long-Term Improvement of Disease-Specific Outcomes in a Phase 2 Trial

2020 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (2)
Phase 1 Clinical Study of Mgta-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs without G-CSF

2020 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (1)
FRI0235 PHASE 1 CLINICAL STUDY OF MGTA-145 IN COMBINATION WITH PLERIXAFOR SHOWS RAPID SINGLE-DAY MOBILISATION AND COLLECTION OF CD34+ HAEMATOPOIETIC STEM CELLS WITHOUT G-CSF

2020 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

2019 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Patients with Inherited Metabolic Disorders (IMD) transplanted with MGTA-456, a CD34+ Expanded Cell Therapy Product, Show Rapid Engraftment in Preliminary Phase 2 Trial Results (P4.6-059)

2019 Neurology
Show All
- Source
- Cite
- Save
Citations (0)
Elderly do benefit from induction chemotherapy: High dose mitoxantrone‐based (“5 + 1”) induction chemotherapy regimen in newly diagnosed acute myeloid leukemia

2019 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (5)
Robust Engraftment with Mgta-456, a CD34+ Expanded Cell Therapy Product in Patients with Inherited Metabolic Disorders (IMD): Preliminary Phase 2 Trial Results

2019 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (0)
Preliminary results demonstrate engraftment with minimal neutropenia with MGTA-456, a CD34expanded cord blood (CB) product in patients transplanted for inherited metabolic disorders (IMD)

2019 Molecular Genetics and Metabolism
Show All
- Source
- Cite
- Save
Citations (0)